Open AccessPhase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma
Author(s) -
R. Donald Harvey,
Bradley Curtis Carthon,
Colleen Lewis,
M. Shahadat Hossain,
Chao Zhang,
Zhengjia Chen,
Wayne Harris,
Olatunji B. Alese,
Walid Labib Shaib,
Mehmet Asım Bilen,
David H. Lawson,
Christina Wu,
Conor E. Steuer,
Bassel F. ElRayes,
Fadlo R. Khuri,
Sagar Lonial,
Edmund K. Waller,
Suresh S. Ramalingam,
Taofeek K. Owonikoko
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0988-2
Subject(s) - medicine , everolimus , neutropenia , lenalidomide , pharmacodynamics , rash , oncology , progressive disease , adverse effect , gastroenterology , pharmacology , pharmacokinetics , toxicity , multiple myeloma , chemotherapy
Purpose: The combination of a mammalian target of rapamycin inhibitor and lenalidomide showed enhanced preclinical cytotoxicity. We conducted a phase 1 study in advanced solid tumour patients to assess safety, efficacy and pharmacodynamic (PD) outcomes.